Interactions between antiepileptics and second-generation antipsychotics

被引:68
|
作者
de Leon, Jose [1 ,3 ]
Santoro, Vincenza [2 ]
D'Arrigo, Concetta [2 ]
Spina, Edoardo [2 ]
机构
[1] Univ Kentucky, Mental Hlth Res Ctr, Eastern State Hosp, Lexington, KY 40508 USA
[2] Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Messina, Italy
[3] Univ Granada, Inst Neurosci Psychiat & Neurosci Res Grp CTS 549, Granada, Spain
关键词
amisulpride; anticonvulsants; antipsychotics; aripiprazole; asenapine; bipolar disorder; carbamazepine; clozapine; drug interactions; eslicarbazepine; ethosuximide; felbamate; gabapentin; iloperidone; lacosamide; lamotrigine; levetiracetam; lurasidone; olanzapine; oxcarbazepine; paliperidone; pharmacokinetics; phenobarbital; phenytoin; pregabalin; primidone; quetiapine; retigabine; risperidone; rufinamide; stiripentol; tiagabine; topiramate; valproate; vigabatrin; ziprasidone; zonisamide; STEADY-STATE PHARMACOKINETICS; DRUG-MONITORING SERVICE; PLASMA CLOZAPINE CONCENTRATIONS; RANDOMIZED CONTROLLED-TRIAL; OLANZAPINE SERUM CONCENTRATIONS; MAJOR DEPRESSIVE DISORDER; PREGNANE-X RECEPTOR; BIPOLAR I DISORDER; OF-THE-LITERATURE; VALPROIC ACID;
D O I
10.1517/17425255.2012.660918
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP pharmacodynamic mechanisms are poorly understood. AED--SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder. Areas covered: This article provides a comprehensive review of the interactions between antiepileptics and second-generation antipsychotics. The authors cover pharmacokinetic AED--SGAP DI studies, the newest drug pharmacokinetics in addition to the limited pharmacodynamic DI studies. Expert opinion: Dosing correction factors and measuring SGAP levels can help to compensate for the inductive properties of carbamazepine, phenytoin, phenobarbital and primidone. Further studies are needed to establish the clinical relevance of combining: i) AED strong inducers with amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and olanzapine; iii) high doses of oxcarbazepine (1500 mg/day) or topiramate (>= 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in bipolar disorder, ii) combining topiramate or zonisamide with SGAPs may decrease weight gain. Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and swallowing disturbances. A few AED--SGAP combinations may increase risk for osteoporosis or nausea. Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leukopenia and heat stroke. The authors believe that collaboration is needed from drug agencies and pharmaceutical companies, the clinicians using these combinations, researchers with expertise in meta-analyses, grant agencies, pharmacoepidemiologists and DI pharmacologists for future progression in this field.
引用
收藏
页码:311 / 334
页数:24
相关论文
共 50 条
  • [31] Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
    Caruso, Giuseppe
    Grasso, Margherita
    Fidilio, Annamaria
    Tascedda, Fabio
    Drago, Filippo
    Caraci, Filippo
    PHARMACEUTICALS, 2020, 13 (12) : 1 - 20
  • [32] A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
    Leucht, Stefan
    Komossa, Katja
    Rummel-Kluge, Christine
    Corves, Caroline
    Hunger, Heike
    Schmid, Franziska
    Lobos, Claudia Asenjo
    Schwarz, Sandra
    Davis, John M.
    AMERICAN JOURNAL OF PSYCHIATRY, 2009, 166 (02) : 152 - 163
  • [33] Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use
    Fleischhacker, WW
    PSYCHOPHARMACOLOGY, 2003, 169 (02) : 207 - 210
  • [34] Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use
    W. Wolfgang Fleischhacker
    Psychopharmacology, 2003, 169 : 207 - 210
  • [35] New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
    Citrome, Leslie
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (07) : 767 - 783
  • [36] Practical guidelines for the use of long-acting injectable second-generation antipsychotics
    Jarema, Marek
    Wichniak, Adam
    Dudek, Dominika
    Samochowiec, Jerzy
    Bienkowski, Przemyslaw
    Rybakowski, Janusz
    PSYCHIATRIA POLSKA, 2015, 49 (02) : 225 - 241
  • [37] Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders
    Steen, Nils Eiel
    Aas, Monica
    Simonsen, Carmen
    Dieset, Ingrid
    Tesli, Martin
    Nerhus, Mari
    Gardsjord, Erlend
    Morch, Ragni
    Agartz, Ingrid
    Melle, Ingrid
    Ueland, Torill
    Spigset, Olav
    Andreassen, Ole A.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2017, 18 (06) : 471 - 482
  • [38] A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia
    Taylor, David
    Hayhurst, Karen
    Kerwin, Robert
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (03) : 133 - 136
  • [39] Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder
    Vincenzi, Brenda
    Greene, Claire M.
    Ulloa, Melissa
    Parnarouskis, Lindsey
    Jackson, John W.
    Henderson, David C.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2016, 22 (03) : 175 - 182
  • [40] Second-generation antipsychotics and bone turnover in schizophrenia
    Okita, Kyoji
    Kanahara, Nobuhisa
    Nishimura, Motoi
    Yoshida, Toshihiko
    Yasui-Furukori, Norio
    Niitsu, Tomihisa
    Yoshida, Taisuke
    Ishikawa, Masatomo
    Kimura, Hiroshi
    Nomura, Fumio
    Iyo, Masaomi
    SCHIZOPHRENIA RESEARCH, 2014, 157 (1-3) : 137 - 141